0Y3M

Prothena LSE:0Y3M Stock Report

Last Price

US$50.66

Market Cap

US$2.8b

7D

-9.9%

1Y

44.8%

Updated

24 Jan, 2023

Data

Company Financials +

0Y3M Stock Overview

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States.

0Y3M fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Prothena Corporation plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Prothena
Historical stock prices
Current Share PriceUS$50.66
52 Week HighUS$65.23
52 Week LowUS$25.27
Beta0.50
1 Month Change-10.72%
3 Month Change-14.38%
1 Year Change44.78%
3 Year Changen/a
5 Year Change13.66%
Change since IPO15.01%

Recent News & Updates

Recent updates

Shareholder Returns

0Y3MGB BiotechsGB Market
7D-9.9%-2.6%-1.1%
1Y44.8%-23.7%-3.9%

Return vs Industry: 0Y3M exceeded the UK Biotechs industry which returned -23.2% over the past year.

Return vs Market: 0Y3M exceeded the UK Market which returned -2.5% over the past year.

Price Volatility

Is 0Y3M's price volatile compared to industry and market?
0Y3M volatility
0Y3M Average Weekly Movement9.7%
Biotechs Industry Average Movement8.3%
Market Average Movement5.1%
10% most volatile stocks in GB Market10.8%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0Y3M is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: Insufficient data to determine 0Y3M's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
201282Gene Kinneyhttps://www.prothena.com

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson’s disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer’s disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease.

Prothena Corporation plc Fundamentals Summary

How do Prothena's earnings and revenue compare to its market cap?
0Y3M fundamental statistics
Market CapUS$2.84b
Earnings (TTM)-US$156.48m
Revenue (TTM)US$5.15m

551.9x

P/S Ratio

-18.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
0Y3M income statement (TTM)
RevenueUS$5.15m
Cost of RevenueUS$120.75m
Gross Profit-US$115.59m
Other ExpensesUS$40.88m
Earnings-US$156.48m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.03
Gross Margin-2,242.82%
Net Profit Margin-3,036.03%
Debt/Equity Ratio0%

How did 0Y3M perform over the long term?

See historical performance and comparison